Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Study Summary

The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current subprotocols include the following: Subprotocol A: RMC-6236 + 5-fluorouracil-based regimens Subprotocol B: RMC-6236 + cetuximab with or without mFOLFOX6 Subprotocol C: RMC-6236 + gemcitabine + nab-paclitaxel Subprotocol D: RMC-9805 with or without RMC-6236 + 5-fluorouracil-based regimens Subprotocol E: RMC-9805 with or without RMC-6236 + cetuximab with or without mFOLFOX6 Subprotocol F: RMC-9805 with or without RMC-6236 + gemcitabine + nab-paclitaxel

Conditions

Colorectal Cancer CRC Pancreatic Ductal Adenocarcinoma PDAC Gastrointestinal Cancer Metastatic Pancreatic Ductal Adenocarcinoma

Interventions / Drugs

RMC-6236 mFOLFOX6 regimen bevacizumab mFOLFIRINOX regimen cetuximab gemcitabine nab-paclitaxel RMC-9805

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment1130 participants

Primary Completion—

Lead SponsorRevolution Medicines, Inc.

Data Retrieved2026-04-11 04:26:28.070739+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.